SLCO1B3 and hepatocellular carcinoma: The results indicated that the 6-year OS and DFS of 19 (38%) OATP1B3-low HCC patients with TNM stage I/II were significantly lower than those of 31 (62%) OATP1B3-high HCC patients (Fig. 5a and b).